Patients receiving chemotherapy are severely immunocompromised and infections are among the greatest causes of toxicity and death in this population. These experimental treatments could reduce infections among vulnerable patients, Frankfurt said.

“Infections are a serious risk for these patients, so any method to reduce infection will be valuable,” said Frankfurt.